Bionano Genomics, Inc. (BNGO) News
Filter BNGO News Items
BNGO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNGO News Highlights
- For BNGO, its 30 day story count is now at 6.
- Over the past 23 days, the trend for BNGO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about BNGO are DEC, CMA and KT.
Latest BNGO News From Around the Web
Below are the latest news stories about BIONANO GENOMICS INC that investors may wish to consider to help them evaluate BNGO as an investment opportunity.
Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease ResearchSAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ software for applications in constitutional genetic disease. The latest analysis pipeline, Bionano Solve 3.8.1, enhances the sensitivity and specificity for structural variation (SV) detection from OGM data, which, when combined with copy number variant (CNV) analysis capabilities introduced in July |
Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and KaryotypingKey findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5% of samples (41/200); combination of chromosomal microarray analysis (CMA) and karyotyping (KT) detected pathogenic SVs in 19.5% of samples (39/200)Compared to CMA and KT combined in this prospective cohort, OGM had the following performance: Sensitivity: 97.4%Specificity: 100%Positive Predictive Value (PPV): 100%Negative Predictive Value (NPV): 99. |
Cancers Journal Publishes Special Issue Dedicated to OGM’s Impact on Hematological Malignancy ResearchSAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company’s optical genome mapping (OGM) workflow. The issue, which features guest editors Dr. Adam Smith from University of Toronto, Dr. Gordana Raca from Children’s Hospital Los Angeles, and Dr. Alexander Hoischen from Radboud University Medical Center, includes eight peer-reviewed publications, with three additional p |
Bionano Laboratories Announces Publication of the Analytical Validation of its OGM-Based Laboratory Developed Test for Hematological Malignancies and Additional Multi-Site Technical Evaluation of OGMSAN DIEGO, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication of a study covering the analytical validation of its laboratory developed test (LDT), marketed as OGM-Dx™ HemeOne. This LDT is based on optical genome mapping (OGM) analysis of blood or bone marrow samples to detect structural variants (SVs) of diagnostic and prognostic utility in individuals with a new or an existing diagnosis of a hematological malignancy. The publication also included a multi-sit |
Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual MeetingA platform presentation will feature Dr. Enze Liu from the Indiana University School of Medicine sharing findings from a study on the use of optical genome mapping (OGM) to detect structural variants (SVs) in multiple myelomaThirteen scientific posters featuring results from OGM applications in myeloid cancers, acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and hematological malignancy research will be presented at the conference SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- |
Wealth Accumulation: 3 Stocks with Multibagger PotentialAfter fears pushed many stocks with great potential to very low levels, it's a great time to buy names that could become multibagger stocks. |
Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHDSAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD). The publication describes the evaluation of an OGM-based laboratory developed test (LDT) including the assessment of the accur |
Bionano Announces Publication Demonstrating Utility of OGM to Assess Genome Integrity of CRISPR-Edited Cells as Part of Gene Therapy DevelopmentSAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations (SVs) introduced by CRISPR-Cas9 gene editing of CD4+ T-cells that could potentially limit the therapeutic use of such edited cells. The research study authors used OGM in combination with drop-off digital PCR (ddPCR) to assess genome integrity of cells that were edited by CRISPR to restore gene fun |
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
LeddarTech Appoints Chris Stewart as Chief Financial OfficerQUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer (“CFO”). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly |